Management of children and adolescents receiving CAR-T cell therapy for acute lymphoblastic leukemia

DOI Web Site PubMed
  • IMAI Chihaya
    Department of Pediatrics, Faculty of Medicine, University of Toyama

Bibliographic Information

Other Title
  • 小児・思春期の急性リンパ性白血病に対するCAR-T細胞療法の実際
  • ショウニ ・ シシュンキ ノ キュウセイ リンパセイ ハッケツビョウ ニ タイスル CAR-Tサイボウ リョウホウ ノ ジッサイ

Search this article

Description

<p>Tisagenlecleucel, a commercially available CD19-targeted CAR-T cell product, has dramatically changed the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). Tisagenlecleucel infusion has been linked to distinct acute adverse events, including cytokine release syndrome, neurotoxicity, hemophagocytic lymphohistiocytosis and prolonged pancytopenia, which are rare with cytocidal chemotherapy. In addition, recent retrospective studies have revealed pre-infusion prognostic factors including high tumor burden (bone marrow leukemia cell fraction ≥5%) and non-response to blinatumomab, another CD19-targeting agent. Not only physicians providing CAR-T cell therapy but also those referring patients for this therapy should thoroughly understand the indications and limitations, characteristic acute complications, pre-treatment factors affecting prognosis, and late complications. This article outlines the current understanding regarding the use of tisagenlecleucel in children and adolescents with B-ALL.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 65 (9), 1164-1173, 2024

    The Japanese Society of Hematology

Keywords

Details 詳細情報について

Report a problem

Back to top